Walleye Trading’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-6,100
Closed -$358K 5635
2023
Q4
$358K Buy
6,100
+4,500
+281% +$253K ﹤0.01% 3357
2023
Q3
$69.7K Sell
1,600
-2,200
-58% -$78.5K ﹤0.01% 4115
2023
Q2
$137K Sell
3,800
-800
-17% -$33K ﹤0.01% 3618
2023
Q1
$171K Buy
+4,600
New +$207K ﹤0.01% 3609
2022
Q4
Sell
-19,300
Closed -$1.35M 5550
2022
Q3
$1.35M Buy
19,300
+17,300
+865% +$1.28M ﹤0.01% 2016
2022
Q2
$134K Buy
2,000
+700
+54% +$44.5K ﹤0.01% 3980
2022
Q1
$107K Sell
1,300
-1,500
-54% -$153K ﹤0.01% 4206
2021
Q4
$411K Buy
2,800
+700
+33% +$109K ﹤0.01% 3149
2021
Q3
$372K Buy
+2,100
New +$338K ﹤0.01% 3228
2021
Q1
Sell
-200
Closed -$44K 5446
2020
Q4
$44K Buy
+200
New +$43.2K ﹤0.01% 4217
2020
Q1
Sell
-8,600
Closed -$1.11M 4724
2019
Q4
$1.11M Buy
8,600
+300
+4% +$28.9K 0.01% 1707
2019
Q3
$647K Sell
8,300
-900
-10% -$84.5K 0.01% 1932
2019
Q2
$948K Buy
9,200
+3,800
+70% +$296K 0.01% 1647
2019
Q1
$396K Sell
5,400
-3,400
-39% -$231K ﹤0.01% 2456
2018
Q4
$373K Buy
+8,800
New +$351K ﹤0.01% 2783

Other funds holding MRTX

Walleye Trading's MRTX Position: Q1 2024 in Review

Walleye Trading sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 2,425 shares — an estimated $142K sold.

Walleye Trading first reported a position in MRTX in Q3 2016 and held it in 7 quarters. The position peaked at $1.09M in Q4 2019. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Walleye Trading reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Walleye Trading sold 2,425 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $142K.
  • Walleye Trading first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2016 and held it in 7 quarters.
  • Walleye Trading's Mirati Therapeutics, Inc. Common Stock position peaked at $1.09M in Q4 2019.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Walleye Trading's 13F filing for Q1 2024, filed 15 May 2024.